The role of mast cell in pterygium recurrence

Year 2019, Volume: 44 Issue: Supplement 1, 108 - 112, 29.12.2019

Meydan Turan , Gülay Turan

https://doi.org/10.17826/cumj.554232

Abstract

Purpose: To investigate the role in pterygium recurrence of mast cell, which is known to play a role in inflammatory and immunological events, we aimed to determine the mast cell number in primary and recurrent pterygium tissue samples and to determine its relationship with angiogenesis.

Materials and Methods: The study included 61 patients with pterygium who underwent primary pterygium excision with a bare sclera technique, but recurrent after a while. Primary and recurrent pterygium tissue samples of the same patient were examined histopathologically. The mean mast cell count was calculated by counting from 3 different areas under light microscope at 400 x magnification. In addition, the number of vessels was scored at 200x magnification.

Results: 34 of the patients were male and 27 were female. The mean age was 57.02 ± 7.96. The mean mast cell count was 8.46±2.52 in the primary pterygium tissue and 14.07±3.05 in the recurrent pterygium tissue. The mean vascular count was 12.90 ± 3.17 in primary pterygium tissue and 16.21 ± 2.24 in recurrent pterygium. Statistical analysis revealed a significant increase in the number of mast cells and vascular number in the recurrent pterygium. Mast cell number and vascularity were correlated in primary pterygium and recurrent pterygium tissue samples.

Conclusion: Increased mast cell in pterygium tissue may play an important role in the recurrence of pterygium. Determining mast cell count in preventing pterygium recurrence may be important.

Keywords

Mast cell, Pterygium, Recurrence, Angiogenesis

Pterjium nüksünde mast hücresinin rolü

Abstract

Amaç: İnflamatuar ve immünolojik olaylarda rol oynadığı bilinen mast hücresinin pterygium nüksündeki rolünü araştırmak için primer ve tekrarlayan pterygium doku örneklerinde mast hücre sayısını belirlemeyi ve anjiyogenez ile ilişkisini saptamayı amaçladık.

Gereç ve Yöntem: Çalışmaya çıplak sklera tekniği ile primer pterjiyum eksizyonu yapılan, ancak bir süre sonra tekrarlayan pterjiyumlu 61 hasta dahil edildi. Aynı hastanın primer ve tekrarlayan pterygium doku örnekleri histopatolojik olarak incelendi. Ortalama mast hücre sayısı, 400x büyütmede ışık mikroskobu altında 3 farklı alandan sayılarak hesaplandı. Ek olarak, damarların sayısı 200x büyütmede skorlandı.

Bulgular: Hastaların 34'ü erkek, 27'si kadındı. Yaş ortalaması 57.02 ± 7.96 yıl idi. Ortalama mast hücre sayısı, primer pterjiyum dokusunda 8.46 ± 2.52, tekrarlayan pterjiyum dokusunda 14.07 ± 3.05 idi. Ortalama vasküler sayı primer pterjiyum dokusunda 12.90 ± 3.17 ve tekrarlayan pterjiyumda 16.21 ± 2.24 idi. İstatistiksel analiz, tekrarlayan pterjiyumda mast hücre sayısında ve vasküler sayıda anlamlı bir artış olduğunu gösterdi. Primer pterjiyum ve tekrarlayan pterjiyum doku örneklerinde mast hücre sayısı ve vaskülerite korelasyon göstermekteydi. 

Sonuç: Pterjium dokusunda artmış mast hücresi, pterjiumun nüksünde önemli bir rol oynayabilir. Pterjium nüksünün önlenmesinde mast hücre sayısının belirlenmesi önemli olabilir.

Keywords

Mast hücresi, Nüks, Pterjiyum, Anjiyogenez

References

• 1. Kase S, Takahashi S, Sato I, Nakanishi K, Yoshida K, Ohno S. Expression of p27 (KIP1) and cyclin D1, and cell proliferation in human pterygium. Br J Ophthalmol. 2007; 91:958-61. Comment in: Br J Ophthalmol. 2008;92:157.
• 2. Di Giriloma N, Chui J, Coreneo MT, Wakefield D. Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases. Prog Retin Eye Res. 2004;23:195–289.
• 3. Girolama ND, Kumar RK, Cornea MT, Wakefield D. UVB. Mediated indication of interleukin-6 and 8 in pterigia and cultured human pterigium epithelial cells. Inves Opthalmol Vis Sci. 2002;143:3430–37.
• 4. Galli SJ. New concepts about the mast cell. N Engl J Med. 1993;328:257-65.
• 5. Pinkerton OD, Hokama Y, Shigemura LA. Immunologic basis for the pathogenesis of pterygium. Am J Ophthalmol. 1984;98:225-8.
• 6. Okayama Y, Kawakami T. Development, migration, and survival of mast cells. Immunol Res. 2006;34:97-115.
• 7. Da Silva CA, Reber L, Frossard N. Stem cell factor expression, mast cells and inflammation in asthma. Fundam Clin Pharmacol. 2006;20:21-39.
• 8. Ribatti D, Crivellato E, Roccaro AM, Ria R, Vacca A. Mast cell contribution to angiogenesis related to tumour progression. Clin Exp Allergy. 2004;34:1660-4.
• 9. Seifert P, Sekundo W. Capillaries in the epithelium of pterygium. Br J Ophthalmol. 1998;82:77–81.
• 10. Ribatti D, Finato N, Crivellato E, Marzullo A, Mangieri D, Nico B, et al. Neovascularization and mast cells with tryptase activity increase simultaneously with pathologic progression in human endometrial cancer. Am J Obstet Gynecol. 2005; 193:1961–5.
• 11. Butrus SI, Ashraf MF, Laby DM, Rabinowitz AI, Tabbara SO, Hidayat AA. Increased numbers of mast cells in pterygia. Am J Ophthalmol. 1995;119:236-7.
• 12. Grutzkau A, Kruger-Krasagakes S, Baumeister H, Schwarz C, Kogel H, Welker P et al. Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF 206. Mol Biol Cell. 1998;9:875–84.
• 13. Di Girolamo N, Coroneo MT, Wakefield D. UVB-elicited induction of MMP-1 expression in human ocular surface epithelial cells is mediated through the ERK1/2 MAPK-dependent pathway. Invest Ophthalmol Vis Sci. 2003;44:4705-14.
• 14. Cameron ME. Histology of pterygium: an electron microscopic study. Br J Ophthalmol. 1983;67:604-8.
• 15. Ang LP, Chua JL, Tan DT. Current concepts and techniques in pterygium treatment. Curr Opin Ophthalmol. 2007;18:308-13.
• 16. Kareem AA, Farhood QK, Alhammami HA. The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium. Clin Ophthalmol. 2012;6:1849-54.
• 17. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-α/cachectin. Nature. 1990:346;274-6.
• 18. Zhong Y, Ding K, Ye W. [The relation between expression of basic fibroblast growth factor and mast cells in pterygium]. Zhonghua Yan Ke Za Zhi. 2001;37:455-7. Chinese.
• 19. Ribatti D, Crivellato E. Mast cells, angiogenesis, and tumour growth. Biochim Biophys Acta. 2012;1822:2-8.
• 20. Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG et al. Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest. 1997; 99: 2691–700.
• 21. Hallgren J, Estrada S, Karlson U, Alving K, Pejler G. Heparin antagonists are potent inhibitors of mast cell tryptase. Biochemistry. 2001;40:7342–9.
• 22. Ribatti D, Nico B, Maxia C, Longo V, Murtas D, Mangieri D et al. Neovascularization and mast cells with tryptase activity increase simultaneously in human pterygium. J Cell Mol Med. 2007;11:585-9.
• 23. Aspiotis M, Tsanou E, Gorezis S, Ioachim E, Skyrlas A, Stefaniotou M, et al. Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1. Eye (Lond). 2007;21:1095-101.
• 24. Liang K, Jiang Z, Zhao B, Shen J, Huang D, Tao L. The expression of vascular endothelial growth factor in mast cells promotes the neovascularisation of human pterygia. Br J Ophthalmol. 2012;96:1246-51.
• 25. Celebi AR, Ozbey C, Mirza GE. The role of mast cells in vascularized recurrent pterygium. Arq Bras Oftalmol. 2014;77:285-287.
• 26. Karahan N, Baspınar S, Candır O. Pterjium ve nüks pterjiumlardaki mast hücreleri. MN Oftalmoloji. 2006;13:225-7.
• 27. Tan DT, Liu YP, Sun L. Flow cytometry measurements of DNA content in primary and recurrent pterygia. Invest Ophthalmol Vis Sci. 2000;41:1684-6.